Who owns Allogene Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ALLO from SEC Form 13F filings across 209 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 209 institutions disclosed 312.7M shares of Allogene Therapeutics, Inc. worth $652.0M — about 95.1% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
209
13F holders
$652.0M
value, 2026 filers
95.1%
of shares outstanding (312.7M sh)
33
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ALLO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 30.1M | $62.7M | 0.0% | 9.2% | +57.9% |
| 2 | Frazier Life Sciences Management, L.P. | 22.4M | $46.7M | 1.0% | 6.8% | +491.2% |
| 3 | Pfizer Inc | 22.0M | $46.9M | 27.5% | 6.7% | 0.0% |
| 4 | STATE STREET CORP | 19.0M | $39.6M | 0.0% | 5.8% | +119.7% |
| 5 | TPG GP A, LLC | 18.7M | $38.9M | 0.8% | 5.7% | 0.0% |
| 6 | Sio Capital Management, LLCNEW | 13.3M | $27.7M | 4.6% | 4.1% | new |
| 7 | PRIMECAP MANAGEMENT CO/CA/ | 13.1M | $27.3M | 0.0% | 4% | +56.6% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 12.2M | $25.3M | 0.0% | 3.7% | +75.8% |
| 9 | FMR LLC | 12.0M | $25.0M | 0.0% | 3.7% | +655.4% |
| 10 | CITADEL ADVISORS LLC | 10.1M | $21.0M | 0.0% | 3.1% | +48.5% |
| 11 | TWO SIGMA INVESTMENTS, LP | 7.8M | $16.2M | 0.0% | 2.4% | +44.8% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 7.0M | $14.7M | 0.0% | 2.1% | +70.9% |
| 13 | GOLDMAN SACHS GROUP INC | 6.1M | $12.8M | 0.0% | 1.9% | +122.3% |
| 14 | GordonMD Global Investments LP | 5.3M | $11.0M | 5.3% | 1.6% | +270.5% |
| 15 | MARSHALL WACE, LLP | 5.1M | $10.6M | 0.0% | 1.5% | +47.8% |
| 16 | Patient Square Capital LP | 5.0M | $10.5M | 1.6% | 1.5% | +46.4% |
| 17 | Aberdeen Group plc | 5.0M | $10.4M | 0.0% | 1.5% | +242.1% |
| 18 | MILLENNIUM MANAGEMENT LLC | 4.8M | $10.1M | 0.0% | 1.5% | +45.8% |
| 19 | D. E. Shaw & Co., Inc. | 4.7M | $9.8M | 0.0% | 1.4% | +70.4% |
| 20 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.6M | $9.7M | 0.0% | 1.4% | -13.8% |
| 21 | MORGAN STANLEY | 4.5M | $9.4M | 0.0% | 1.4% | +351.5% |
| 22 | Woodline Partners LP | 4.5M | $9.4M | 0.0% | 1.4% | +28.5% |
| 23 | Candriam S.C.A. | 4.3M | $9.0M | 0.0% | 1.3% | +44.7% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.2M | $8.8M | 0.0% | 1.3% | +148.6% |
| 25 | RENAISSANCE TECHNOLOGIES LLC | 3.8M | $8.0M | 0.0% | 1.2% | +79.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.